Trial Profile
Study of no Inferiority Between Two Doses (0.500mg and 0.625mg) of Bevacizumab Intravitreal in the Treatment of Retinopathy of Prematurity Type 1
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 16 May 2014 New trial record